A comprehensive review on the history, uses, and safety of onabotulinum toxin type A (Botox). Issue 4 (20th October 2022)

• Record Type: Journal Article
• Authors: Patel, Kevin R.; Rastogi, Supriya; Prather, Heidi B.
• Other Names: Lain Edward guestEditor.
• Is Part Of: Dermatological reviews. Volume 3:Issue 4(2022)
• Page Start: 180
• Page End: 196
• Publication Date: 2022-10-20
• Subjects: Botox -- botulinum -- botulinum neurotoxin type A -- crow's feet lines -- depressor anguli oris -- forehead lines -- glabellar lines -- neurotoxin -- onabotulinumtoxinA -- overactive bladder -- perioral lines -- rhytides -- temporomandibular disorders -- wrinkles; Dermatology -- Periodicals; Electronic journals; 616.5
• DOI: 10.1002/der2.158
• Languages: English
• ISSNs: 2637-7489

Abstract

Abstract: OnabotulinumtoxinA (ONA), trademarked under the brand name Botox, is a widely studied botulinum neurotoxin currently used for diverse cosmetic and noncosmetic therapeutic treatments. ONA was the first in a growing market of injectable neuromodulators to be studied for medical use. First introduced to the cosmetic marketplace in 2002 by the U.S. Food and Drug Administration for clinical indication of wrinkle correction for glabellar frown lines, ONA has proven to be an invaluable tool in the armamentarium of aesthetic medicine. The most commonly approved dermatologic uses of ONA include facial rhytidosis and hyperhidrosis with ongoing phase 2B studies for masseter hypertrophy. Nondermatologic applications include temporomandibular disorders, strabismus, cervical dystonia, blepharospasm, spasticity, migraines, overactive bladder, and incontinence. Off‐label uses of ONA are well studied in skin disorders, such as rosacea, and other indications, such as Frey's syndrome, and depression. Further, multiple studies have illustrated an improvement in quality of life and self‐esteem with ONA treatment. The favorable side effect profile with minimal adverse effects reinforces that ONA is a safe and effective treatment option with a diverse portfolio of clinically accepted applications.